Director's Dealing • Nov 19, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION | ||
|---|---|---|
| Washington, D.C. 20549 |
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
OMB APPROVAL
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
Instruction 10. (Print or Type Responses)
| 1. Name and Address of Reporting Person * Phillip Frost, M.D., ET AL |
2. Issuer Name and Ticker or Trading Symbol OPKO Health, Inc. [ OPK ] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |
||
|---|---|---|---|---|
| (Last) OPKO Health, Inc. 4400 Biscayne Blvd. |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 11/18/2025 |
X Director X 10% Owner X Officer (give title below) Other (specify below) CEO & Chairman |
| Miami, FL 33137 | (Street) | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
|
| (City) | (State) | (Zip) |
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month /Day/Year) |
2A. Deemed Execution Date, if any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day /Year) |
Code | V | Amount | (A) or (D) |
Price | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
|||
| Common Stock | 11/18/2025 | P | 410 | A | \$ 1.245 | 214,386,858 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 49,590 | A | \$ 1.25 | 214,436,448 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 66,635 | A | \$ 1.255 | 214,503,083 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | A | 46,700 | A | \$ 1.26 | 214,549,783 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 15,000 | A | \$ 1.265 | 214,564,783 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 1,772 | A | \$ 1.27 | 214,566,555 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 212,608 | A | \$ 1.275 | 214,779,163 | I | See Footnote (1) |
||
| Common Stock | 11/18/2025 | P | 69,728 | A | \$ 1.28 | 214,848,891 | I | See Footnote |
| (1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock | 11/18/2025 | P | 428 | A | \$ 1.2847 | 214,849,319 | I | See Footnote (1) |
| Common Stock | 11/18/2025 | P | 83,556 | A | \$ 1.285 | 214,932,875 | I | See Footnote (1) |
| Common Stock | 11/18/2025 | P | 1 | A | \$ 1.2859 | 214,932,876 | I | See Footnote (1) |
| Common Stock | 11/18/2025 | P | 33,572 | A | \$ 1.29 | 214,966,448 | I | See Footnote (1) |
| Common Stock | 3,568,951 | D | ||||||
| Common Stock | 30,127,177 | I | See Footnote (2) |
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month /Day/Year) |
3A. Deemed Execution Date, if any (Month/Day /Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially |
10. Ownership Form of Derivative Security: |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
Owned Following Reported Transaction (s) (Instr. 4) |
Direct (D) or Indirect (I) (Instr. 4) |
| 1. Name and Address of Reporting Person* Phillip Frost, M.D., ET AL |
|||||
|---|---|---|---|---|---|
| (Last) | OPKO Health, Inc. 4400 Biscayne Blvd. |
(First) | (Middle) | ||
| (Street) Miami |
FL | 33137 | |||
| (City) | (State) | (Zip) | |||
| Relationship of Reporting Person(s) to Issuer | |||||
| X X |
Director | Officer (give title below) CEO & Chairman |
X | 10% Owner Other (specify below) |
|
| 1. Name and Address of Reporting Person* Frost Gamma Investments Trust |
|||||
| (Last) | OPKO Health, Inc. 4400 Biscayne Blvd. |
(First) | (Middle) | ||
| (Street) Miami |
FL | 33137 | |||
| (City) | (State) | (Zip) | |||
| Relationship of Reporting Person(s) to Issuer | |||||
| Director | Officer (give title below) | X | 10% Owner Other (specify below) |
| Phillip Frost, M.D., Individually and as Trustee 11/18/2025 | |
|---|---|
| ** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Name: Frost Gamma Investments Trust
Address:
4400 Biscayne Blvd. Miami, FL 33137
Designated Filer: Phillip Frost, M.D.
Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)
Date of Earliest Transaction: November 18, 2025
Relationship to Issuer: 10% Owner
By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee
Have a question? We'll get back to you promptly.